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Oxidative Stress, and Vascular 
Dysfunction
Ana M. Briones and Rhian M. Touyz
Abstract
The mineralocorticoid receptor (MR) is a transcription factor of the family of 
steroid receptors that classically binds the hormone aldosterone. The contribution 
of MR in the regulation of sodium retention and blood pressure is well known. 
However, MR is expressed in extrarenal tissues including endothelial and vascular 
smooth muscle cells, and its activation leads to vascular remodeling, vascular 
stiffness, and endothelial dysfunction leading to vascular damage, an important 
pathophysiological process in hypertension and other cardiovascular diseases. 
Moreover, MR is expressed in nonvascular cells in close contact with the vascular 
wall including immune cells and adipocytes that might influence vascular function 
and structure. MR activation involves its translocation to the nucleus and regulation 
of gene transcription. In addition, aldosterone exerts rapid non-genomic effects 
mediated by MR-dependent and MR-independent mechanisms. Both genomic and 
non-genomic effects facilitate reactive oxygen species (ROS) production (par-
ticularly by the enzyme NADPH oxidase), inflammation, and fibrosis, which, in 
turn, promote tissue remodeling, vascular stiffening, and endothelial dysfunction. 
Studies with MR antagonists and experimental models with cell-specific knockout 
or overexpression of MR further support a role for aldosterone/MR-mediated 
oxidative stress-dependent processes in vascular damage. This review focuses on 
the relationship between aldosterone/MR signaling and oxidative stress and the 
implications in vascular regulation in health and disease.
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1. Introduction
The mineralocorticoid receptor (MR) classically binds the hormone aldosterone 
and in the kidney regulates sodium retention, volume homeostasis, and blood 
pressure. The MR, originally thought to be expressed only in the kidney, is now 
known to have an extensive extrarenal distribution and is functionally active in the 
cardiovascular and immune systems. MR activation is involved in various cardio-
vascular diseases [1, 2] and has also been implicated in metabolic disorders and 
insulin resistance. At the vascular level, MR is expressed in endothelial and vascular 
smooth muscle cells (VSMC), and its activation leads to vascular remodeling, 
vascular fibrosis, and endothelial dysfunction leading to vascular damage, arterial 
stiffness, and hypertension [1–3]. However, MR is also expressed in nonvascular 
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cells in close contact with the vascular wall including immune cells and adipocytes 
where it influences inflammatory and metabolic processes [4, 5].
The MR is an intracellular receptor that has three domains: (i) an N-terminal 
domain that controls transcriptional activity of the receptor, (ii) the DNA-binding 
domain that influences binding of the specific response element on the promoter of 
MR target genes, and (iii) the ligand-binding domain for aldosterone. Upon activa-
tion, the MR is translocated to the nucleus and further regulates gene transcription 
and translation of proteins by binding to DNA hormone/steroid stimulatory or 
negative response elements [1, 2]. In addition, aldosterone exerts rapid non-
genomic effects mediated by MR-dependent and MR-independent mechanisms [6], 
and recent studies uncovered an MR-dependent suppression of miRNA expression 
resulting in upregulation of vascular miRNA targets [7]. Both genomic and non-
genomic effects promote reactive oxygen species (ROS) production particularly by 
the enzyme NADPH oxidase, as well as inflammation and fibrosis, which, in turn, 
leads to tissue remodeling and vascular stiffening and endothelial dysfunction. This 
review focuses on the relationship between aldosterone/MR signaling and oxidative 
stress and its vascular effects (Figure 1).
2. MR and oxidative stress in vascular cells
Extensive evidence has demonstrated a relationship between MR and redox 
signaling in vascular cells. Animal models including the deoxycorticosterone 
acetate (DOCA)/salt model and the aldosterone/salt model with or without 
nephrectomy exhibit vascular oxidative stress. The significance of ROS in these 
models is supported by studies that demonstrated that MR blockers reduce ROS 
levels in cardiovascular pathologies including hypertension, obesity, atherosclero-
sis, or heart failure. In many of the experimental and human studies, evidence of 
Figure 1. 
At the vascular level, MR is expressed in endothelial (EC) and vascular smooth muscle cells (VSMC). Its 
activation by genomic and rapid non-genomic effects mediated by MR-dependent and MR-independent 
mechanisms leads to activation of NADPH oxidase that produced reactive oxygen species (ROS) leading to 
vascular remodeling, fibrosis, inflammation, and endothelial dysfunction that produces vascular damage and 
arterial stiffness and might participate in hypertension and cardiac and kidney damage.
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altered oxidative stress was often based on a single method to determine oxidative 
stress, i.e., altered gene or protein expression of NADPH oxidase subunits, NADPH 
oxidase activity, lipid peroxidation determinations, fluorescence-based studies, 
etc., and this might explain, at least in part, some divergent findings. Because of 
the complexity of redox biology and difficulties in accurately measuring ROS, 
expert recommendations have been published suggesting that multiple different 
assays need to be used to accurately assess redox status in biological systems and 
experimental models [8]. Here we will not discuss specific methods to measure 
ROS in the context of aldosterone/MR, and the reader is referred to comprehensive 
reviews [8, 9].
Aldosterone increases ROS production in cultured VSMC [10–15] and endo-
thelial cells [16–21]. Moreover, aldosterone infusion into mice or rats increases 
plasma and vascular oxidative stress, and MR blockade reduces ROS production 
in the setting of hypertension, obesity, and other cardiovascular diseases [21–29]. 
Earlier studies identified NADPH oxidase as responsible for increased production 
of vascular ROS, specifically superoxide (O2
−), in the aorta from mineralocorticoid 
(DOCA-salt) hypertensive rats excluding other ROS sources (i.e., uncoupled eNOS 
or xanthine oxidase) as potential contributors [30]. NADPH oxidase is considered 
the major source of ROS in response to aldosterone/MR stimulation in vessels.
The NADPH oxidase (Nox) family is composed of seven Nox isoforms (Nox1–
Nox5 and Duox1 and Duox2); several regulatory subunits p22phox, p47phox, 
Noxo1, p67phox, Noxa1, and p40phox; and the major binding partner Rac. The 
main catalytic function of NADPH oxidases is the generation of ROS. NADPH 
oxidase reduces oxygen to O2
−, with NADPH being the electron donor. Nox-2 is the 
classical Nox that was characterized initially in leukocytes. Nox-1, Nox-2, Nox-4, 
and Nox-5 are expressed in the cardiovascular system with Nox5 not being present 
in rodents. Nox-1, Nox-2, Nox-3, and Nox-5 produce O2
−, while Nox-4, Duox-1, and 
Duox-2 produce H2O2 [31, 32]. In vessels, in addition to vascular cells possessing 
functional Noxes, resident macrophages, neutrophils, and platelets express NADPH 
oxidase, particularly in pathological states. Accordingly, these cells can also contrib-
ute to vascular oxidative stress in disease [32, 33].
2.1 Genomic and non-genomic effects of aldosterone/MR on ROS production
At the vascular level, a combination of aldosterone and high salt caused O2
− 
production in VSMC through upregulation of Nox1 without affecting expression 
of mRNA Nox4, p22phox, and p47phox [11]. In human vein endothelial cells 
(HUVEC), aldosterone increased p47phox transcription, but no effect on transcrip-
tion levels of Nox1, Nox2, Nox4, p22phox, p40phox, or p67phox was observed 
[16]. However, other studies showed that incubation with aldosterone for 24 h 
dose-dependently increased Nox4 mRNA expression in HUVEC [17]. In human 
pulmonary artery endothelial cells, aldosterone increased protein levels of Nox4 
and p22phox as well as H2O2 production [20]. Similarly, in bovine retinal endothe-
lial cells, aldosterone increased mRNA for Nox4 [19], and other studies showed that 
aldosterone administration modulated exclusively p22phox mRNA expression in 
freshly isolated aortic endothelial cells [21]. Aldosterone plus salt infusion into rats 
increased vascular NADPH oxidase activity and expression of p47phox, gp91phox, 
and p22phox [34], and recently, Jia et al. [29] found vascular upregulation of 
Nox2 expression and nitrotyrosine (a marker of nitrosative stress) formation after 
3 weeks of aldosterone infusion in mice. Together, these findings clearly show a 
pattern of vascular NADPH oxidase upregulation by aldosterone at the vascular 
level. This is also supported by the fact that MR antagonists decrease NADPH 
oxidase subunit expression [9]. For example, eplerenone treatment decreased the 
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expression of p22phox, p47phox, and p40phox in a model of high-fat diet [21]. 
Moreover, deletion of MR in specific vascular cell types also downregulates NADPH 
oxidase isoforms (discussed below).
For the rapid MR-dependent aldosterone effects, the MR seems to be localized 
near the plasma membrane, but not directly inserted into it. It is located at the cyto-
solic site associated with scaffolding proteins that are associated with or inserted in 
the cell membrane such as striatin or caveolin-1 [6]. In this location, aldosterone can 
also interact with receptors such as receptor tyrosine kinases including epidermal 
growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), 
and insulin-like growth factor 1 receptor (IGF1R) or G protein-coupled receptors 
(GPCR) such as angiotensin type 1 receptor (AT1) or G protein-coupled estrogen 
receptor 1 (GPER1) [6].
The Src family of non-receptor tyrosine kinases seems to be involved in non-
genomic ROS generation by aldosterone [9]. In cultured VSMC, NADPH oxidase-
dependent ROS generation through non-genomic effects of aldosterone is increased 
in spontaneously hypertensive rats and is dependent on c-Src [10]. A role for c-Src 
and Rac-1 in NADPH oxidase activation in endothelial cells has also been described 
although this effect might be mediated via genomic actions because long incubation 
times were tested [18]. In VSMC, EGFR and PDGFR, but not IGFR, transactivation 
by MR and AT1 activates c-Src that in turn facilitates activation of NADPH oxidase 
and ROS production leading to VSMC migration [35].
Besides receptor tyrosine kinases, GPCR are important partners involved in 
the non-genomic actions of aldosterone. Thus, MR/AT1 receptor interaction has 
been implicated, because MR blockade can inhibit angiotensin II-induced ROS 
production in vascular tissue [22], and more recently, it has been shown that 
AT1a is required for MR-induced endothelial dysfunction and vascular remodel-
ing, oxidative stress, and inflammation [27], although a genomic effect cannot 
be excluded in these studies. In cardiac myocytes, an interaction between MR 
and AT1 participates in aldosterone-induced ROS generation by Nox4 via G 
protein-coupled receptor kinase (GRK) 2 likely via non-genomic actions [36], 
but whether this GRK2-dependent mechanism also occurs in vascular cells is 
unknown. Similarly, there is a paucity of information regarding the novel putative 
aldosterone receptor GPER1 (also known as GPR30) in aldosterone-induced ROS 
production in vascular cells, and the evidence supporting this possibility comes 
from cardiac cells [37, 38].
Non-genomic MR signaling can modulate MR genomic effects [6], thus further 
perpetuating ROS generation in vascular cells.
2.2  Aldosterone/MR/oxidative stress pathway and endothelial and smooth 
muscle cells
Extensive experimental evidence has demonstrated a beneficial effect of aldo-
sterone/MR blockade in vascular damage (i.e., endothelial dysfunction, vascular 
remodeling, and stiffness) and oxidative stress [1–3, 21, 22, 39–42]. As such, it has 
been suggested that many of the beneficial effects of MR antagonist rely, at least in 
part, on its ability to decrease oxidative stress. This is supported by direct evidence 
emerging from studies using models of aldosterone or mineralocorticoid infusion 
together with antioxidant treatments and by the use of transgenic mouse models of 
MR overexpression or deletion.
MR expressed in cerebral artery endothelial cells mediates increased capac-
ity for O2
− production in response to chronically increased systemic levels of 
aldosterone [26]. Moreover, mRNA expression of p22phox, but not gp91phox, 
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was upregulated by aldosterone, and this effect was abolished in endothelial 
cell-specific MR knockout mice (EC-MR-KO) [21], concomitant with improved 
endothelial function. However, in the absence of stimuli, conditional overexpres-
sion of the MR in endothelial cells is not sufficient to increase local vascular or 
systemic oxidative stress [43], suggesting that upregulation of the MR alone is not 
enough to produce increased oxidative stress generation. This is consistent with the 
idea that EC-MR might be vasoprotective in healthy states and that this protection 
is lost when cardiovascular risk factors such as hypertension, obesity, or increased 
aldosterone levels are present, as suggested recently [2, 44] (Figure 2). In support 
of this hypothesis, EC-MR deficiency prevented western diet-induced Nox2, Nox4, 
p22phox, and 3-nitrotyrosine expression, and this was concomitant with reduced 
aortic fibrosis and stiffness and restoration of endothelial nitric oxide synthase 
activation [28]. Similarly, EC-MR deletion prevented resistance vessel endothelial 
dysfunction associated with hyperlipidemia in females, but not in males, and this 
was associated with decreased O2
− generation [45].
Although adult SMC-MR-KO mice show no difference in basal vascular ROS, 
aged SMC-MR-KO mice vessels produce significantly less vascular ROS [7, 46]. 
Moreover, both young and aged SMC-MR-KO mice show attenuated angiotensin 
II-stimulated ROS production [46] which might have contributed to the lower 
blood pressure observed in these mice via improved vascular contraction. More 
recently, an inverse relationship between SMC-MR and miR-155 has been described 
in aging [7], whereby this miRNA would repress the SMC-MR-associated oxidative 
stress also having an impact in vascular function [7]. However, the specific ROS 
source that is modulated by miR-155 is unknown. VSMC-MR was also shown to 
be involved in the progression of heart failure post myocardial infarction, through 
its direct role in oxidative stress-induced coronary endothelial dysfunction and 
in decreased coronary reserve [47]. In this study the antioxidants apocynin and 
superoxide dismutase (SOD) improved endothelium-dependent relaxation of 
Figure 2. 
MR expressed in endothelial cells mediates increased capacity for O2
− production in response to chronically 
increased systemic levels of aldosterone such as those occurring in hypertension, obesity, or diabetes. In aging or 
heart failure after myocardial infarction (HF), SMC-MR facilitates increased ROS production. In addition, 
an inverse relationship between SMC-MR and miR-155 has been described in aging, whereby this miRNA 
would repress the SMC-MR-associated oxidative stress. Whether this is via NADPH oxidase is unknown. In 
these pathologies, both EC and SMC-MR activation facilitate ROS formation that participates in endothelial 
dysfunction, vasoconstriction, vascular remodeling, and fibrosis, the latter being mediated by the increased 
expression of different extracellular matrix proteins and profibrotic factors (CTFG, connective tissue growth 
factor; PAI-1, plasminogen activator inhibitor 1; Fn, fibronectin).
Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine
6
coronary arteries from myocardial infarction mice without affecting relaxation of 
arteries from myocardial infarction-MR-SMC-knockout or treated with finerenone, 
indicating a lower effect of oxidative stress when MR is absent in VSMCs or after 
general MR blockade [47]. Together, these findings point to both endothelial cells 
and VSMC as potential sources of ROS in response to aldosterone or pathological 
conditions that impact vascular function (Figure 2).
Regarding the role of oxidative stress in vascular remodeling and stiffness, it has 
been demonstrated that a combination of aldosterone and high salt caused O2
− pro-
duction and VSMC hypertrophy through the upregulation of Nox1 [11] and antioxi-
dants attenuated aldosterone-induced VSMC senescence and Ki-ras2A expression 
[48]. In addition, it has been suggested that aldosterone augments vascular 
hypertrophic effects of insulin via an MR- and oxidative stress-mediated pathways 
[49]. Aldosterone-induced hypertrophy and perivascular fibrosis were significantly 
ameliorated by long-term treatment with spironolactone or antioxidants [50, 51]. 
However, the profibrotic, but not the hypertrophic, action of aldosterone in resis-
tance arteries was blocked by the antioxidant tempol treatment [23]. Mechanisms 
responsible for these effects likely rely on the ability of aldosterone-derived ROS 
to modulate a number of genes involved in vascular injury including placental 
growth factor, metallothioneins 1 and 2, or connective tissue growth factor [52]. In 
addition, aldosterone increased expression of profibrotic factors fibronectin and 
plasminogen activator inhibitor (PAI)-1 in wild type but not in Nox-1 knockout 
mice [53, 62] (Figure 2). Moreover, tempol treatment inhibited other proinflamma-
tory and profibrotic markers such as osteopontin, intracellular adhesion molecule 1, 
vascular cell adhesion molecule 1, or PAI-1 mRNA expressions that were induced by 
aldosterone infusion in rats [54].
Among the mechanisms responsible for endothelial dysfunction, it is generally 
assumed that the interaction between NO and O2
−, usually from NADPH oxidase, 
leads to ONOO− formation or eNOS uncoupling, thus decreasing NO availability, 
among other mechanisms (for detailed reviews, see [31–33, 55, 56]) (Figure 3). In 
this scenario, aldosterone-induced inhibition of NO production in endothelial cells 
was partially restored by p47phox knockdown using siRNA [16]. Other potential 
mechanisms responsible for aldosterone/MR/ROS-induced endothelial dysfunc-
tion include (i) oxidative posttranslational modification(s) of guanylyl cyclase 
activity that impair sensing of this enzyme by NO [12], (ii) downregulation of the 
antioxidant enzyme glucose-6-phosphate dehydrogenase [57], or (iii) oxidative 
modification of the redox sensitive, functional cysteinyl thiol(s) in the endothelin 
receptor (ETBR) (Cys405) by Nox-4-dependent H2O2, to impair ETB-dependent 
activation of eNOS and decrease synthesis of NO [20]. In this sense, during renal 
ischemia, activation of MR signals Rac1 to increase ROS production in the SMCs 
that diffuse to ECs to induce posttranslational sulfenic acid modification in ETBR 
that impairs eNOS activation and diminishes NO production leading to sustained 
vasoconstriction and reduced kidney perfusion [58]. In addition, cardiomyocyte-
specific overexpression of human MR induces severe coronary endothelial 
dysfunction with decreased NO-mediated relaxing responses to acetylcholine in 
coronary arteries (but not in peripheral arteries), effects prevented by 1-month 
treatment with an MR antagonist, vitamin E/vitamin C, or a NADPH oxidase 
inhibitor [59]. Finally, a role for the epithelial sodium channel in aldosterone-
induced oxidative stress and in endothelium stiffness and endothelial dysfunction 
and fibrosis has also been described [29] (Figure 3). Interestingly, Rac1 is not 
only one of the NADPH oxidase components but also serves as the upregulator of 
MR signaling in the kidney [60]. This Rac1-MR pathway is activated by ROS in 
cardiomyocytes [61] and also plays a crucial role in ROS production and cardiac 
dysfunction [62].
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3. MR and oxidative stress in immune cells
Growing evidence suggests that aldosterone induces vascular monocyte/
macrophage and T-cell infiltration in different pathological states [24, 63, 64]. MR 
is expressed in both macrophages and T cells, where it functions as an important 
transcriptional regulator of cellular phenotype and function and can be activated 
even with normal or low aldosterone levels in pathological conditions [5, 65].
The relationship between immune cells, MR, and oxidative stress was dem-
onstrated in uninephrectomized rats treated for 4 weeks with dietary 1% NaCl 
and aldosterone, where there was an increased H2O2 production by monocytes and 
lymphocytes, upregulation of oxidative stress-inducible tyrosine phosphatase and 
Mn-SOD genes in peripheral blood mononuclear cells, and the presence of 3-nitro-
tyrosine in CD4+ inflammatory cells invading intramural coronary arteries [66]. 
Guzik et al. [67] showed that DOCA/salt-induced hypertension and O2
− production 
in the aorta were blunted in rag−/− mice deficient in T and B lymphocytes. Notably, 
enhanced suppressor regulatory T lymphocytes, which are suppressors of the 
innate and adaptive immune responses, prevented aldosterone-induced endothelial 
dysfunction, vascular remodeling, and oxidative stress [25]. More recently, the key 
role of immune cell MR in oxidative stress generation was demonstrated by Sun 
and coworkers [68] that showed that blood vessels from T-cell MR knockout mice 
had suppressed O2
− production, and this was paralleled by attenuated target organ 
damage including better endothelial function and less vascular hypertrophy and 
fibrosis after angiotensin II infusion. This may be due to a lower proportion of IFN-
γ-producing T cells in the arteries [68]. In fact, T-cell MR facilitates activation of T 
Figure 3. 
Mechanisms responsible for aldosterone/MR-induced endothelial dysfunction. The interaction between NO 
and O2
−, usually from NADPH oxidase, leads to ONOO− formation or eNOS uncoupling, thus decreasing 
NO availability. Other potential mechanisms include oxidative posttranslational modification(s) of guanylyl 
cyclase (GC) activity that impair sensing of this enzyme by NO, downregulation of the antioxidant enzyme 
glucose-6-phosphate dehydrogenase (G6PD), or oxidative modification of the endothelin receptor (ETBR) to 
impair ETB-dependent activation of eNOS and decrease synthesis of NO. In renal ischemia, ROS production 
in the SMCs diffuses to ECs to induce modifications in ETBR that diminishes NO production leading to 
sustained vasoconstriction and reduced kidney perfusion. Also, cardiomyocyte-specific overexpression of human 
MR induces severe coronary endothelial dysfunction with decreased NO-mediated relaxing responses via 
NADPH oxidase-dependent ROS. Epithelial sodium channel (ENac) also participates in aldosterone-induced 
oxidative stress and endothelial dysfunction.
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cells modulating the production of inflammatory cytokines such as IFNγ and IL-6 
[69] that can induce ROS production at vascular level.
Regarding macrophages, it has been shown that aldosterone stimulation of mac-
rophages induces a proinflammatory M1 phenotype [5]. Macrophages from mice 
lacking MR in myeloid cells exhibited a transcription profile of alternative activa-
tion from a M1 phenotype toward a M2 more anti-inflammatory phenotype [70]. 
This might modulate vascular function as NLRP3 inflammasome in macrophages 
explains aldosterone-induced hypercontractility, endothelial dysfunction, and 
hypertrophic remodeling [71], although in this study the specific contribution of 
macrophage-derived ROS was not evaluated. Interestingly, a shift in polarization to 
a M2 phenotype in the EC-MR-KO mice exposed to a western diet was also observed 
[28], suggesting a role for endothelial cells-MR in macrophage function. Regarding 
oxidative stress, aldosterone increases O2
− production and NADPH oxidase activa-
tion in macrophages both in vivo and in vitro [72] and also mitochondrial ROS 
generation [71] that might contribute to the activation of inflammasome in this 
cell type as suggested previously [73]. Notably, aldosterone-induced endothelial 
dysfunction and vascular oxidative stress were decreased in mcsfOp/+, which have 
a low monocyte/macrophage number in the vessel wall [24], suggesting that MR 
activation in macrophages modulates vascular oxidative stress. Interestingly, oxida-
tive stress assessed as Nox2 and p22phox gene expression is equivalently increased 
in the heart of wild-type and mac-MR-KO with L-NAME/salt treatment [74], 
and MR deficiency in macrophages did not influence their oxidative status in the 
context of atherosclerosis [75], suggesting a different contribution of MR-derived 
ROS in different tissues and pathologies. In vivo, MR deficiency in macrophages 
mimicked the effects of MR antagonists and protected against vascular damage 
Figure 4. 
Aldosterone induces vascular monocyte/macrophage and T-cell infiltration in different pathological states such 
as hypertension and obesity. MR is expressed in both macrophages and T cells. T-cell MR facilitates activation 
of T cells modulating the production of inflammatory cytokines such as IFNγ and IL-6 that can induce ROS 
production at vascular level. MR activation in macrophages induces a proinflammatory M1 phenotype leading 
to the production of IL-1β. Either directly or through the production of these proinflammatory cytokines, 
immune cell-derived ROS seems to facilitate vascular remodeling and endothelial dysfunction. MR expression 
is increased in the adipose tissue in obesity. MR in the different cell types included in the adipose tissue (i.e., 
adipocytes, preadipocytes, macrophages) might facilitate oxidative stress and vascular alterations associated 
with obesity.
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caused by L-NAME/angiotensin II [70], and selective deletion of MR in myeloid 
cells limits macrophage accumulation that leads to less VSMC activation and vascu-
lar inflammation and inhibits neointimal hyperplasia and vascular remodeling [76]. 
In both studies, again the specific contribution of macrophage-derived ROS was not 
evaluated.
Together, these findings highlight a key contribution of MR-dependent ROS 
from immune cells in vascular damage. Whether this is due to locally produced ROS 
by infiltrated cells or through the release of proinflammatory cytokines affect-
ing the underlying VSMC or endothelial cells to induce oxidative stress, or both, 
remains unclear (Figure 4).
4. MR and oxidative stress in adipose tissue
Other extrarenal tissue that express MR is the adipose tissue where MR is 
involved in essential processes such as differentiation, autophagy, and adipokine 
secretion [4, 77]. MR expression is increased in adipose tissue of murine models of 
obesity and in obese human subjects, and different studies using MR antagonists 
and also adipocyte-specific MR transgenic mice have demonstrated a key role of 
MR in insulin signaling and inflammation, as reviewed previously [4, 77, 78].
It is well accepted that adipose tissue, particularly perivascular adipose tissue 
(PVAT), modulates vascular health and disease through the release of a number of 
adipokines that affect contractile and relaxant properties, vascular smooth muscle 
cell proliferation and hypertrophy, fibrosis, and inflammation [79]. Among the 
many substances released, ROS such as H2O2 seems to have a pivotal role both in 
physiological and pathological conditions; however, in some disease states such as 
obesity or hypertension, proinflammatory cytokines such as IL-1, IL-6, or TNF-α 
released from PVAT clearly affect vascular tone [79], probably in part through 
increased oxidative stress generation. Thus, in healthy rat mesenteric arteries, 
the anticontractile effect of PVAT was lost following incubation with aldosterone 
(10 minutes and 3 hours), and this was restored by a combination of SOD and 
catalase and by eplerenone, and this is likely dependent on macrophage infiltra-
tion in the PVAT [80]. Moreover, MR blockade reduced ROS production in 3 T3-L1 
adipocytes [81, 82].
Earlier studies showed that the NADPH oxidase subunits p22 and p47phox 
were significantly increased in adipose tissue from ob/ob and db/db obese mice 
compared with lean control mice and that eplerenone treatment suppressed 
this increase [81]. The increase in ROS levels observed in adipose tissue of these 
models of obesity could also be due to the decreased gene expression of the ROS-
eliminating enzymes, catalase, and Cu/Zn-SOD, which were reduced in both ob/
ob and db/db mice and which were also restored by administration of eplerenone 
[81]. Other studies also reported upregulation of antioxidant enzymes (SOD-1 
and catalase) at vascular level by MR blockade in obesity/diabetes [41]. Finally, in 
the adipose tissue of nephrectomized rats, oxidative stress increased, and this was 
reversed by spironolactone [83].
In vivo conditional upregulation of MR in mouse adipocytes led to increased 
production of H2O2 from epididymal adipose tissue likely due to the decrease in 
catalase mRNA levels and the increased Nox-4 mRNA levels without changes in 
Nox-1 and Nox-2 expressions which likely explain changes in vascular contractility 
[84]. Interestingly, adipocyte-specific MR knockout mice (AdipoMR-KO) fed with 
high-fat/high-sucrose diet showed similar levels of 8-isoprostane, p22phox, SOD-
1, or catalase mRNA levels, and they did not show differences in body weight, fat 
weight, glucose tolerance, insulin sensitivity, or inflammation [85]. Similar results 
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were reported by Feraco and coworkers [86] using inducible adipocyte-specific 
deletion of MR fed a 45% high-fat diet although in this study oxidative stress was 
not evaluated. Further studies are warranted to identify the specific contribution 
of MR in the different cell types included in the adipose tissue (i.e., adipocytes, 
preadipocytes, macrophages) as responsible for the MR-dependent inflammation, 
oxidative stress, and metabolic alterations associated with obesity (Figure 4).
5. Clinical relevance
While there is extensive preclinical data indicating that aldosterone-MR signals 
through redox-dependent pathways, there is a paucity of information in humans. 
However, a few clinical studies have suggested that hyperaldosteronism is associated 
with increased concentration of circulating markers of oxidative stress. In patients 
with stable heart failure and in patients with hypertension, higher aldosterone 
levels were associated with systemic evidence of oxidative stress, inflammation, and 
matrix turnover [87]. In heart failure patients, aldosterone-associated cardiovascu-
lar damage and renal fibrosis were linked to decreased production of NO, increased 
oxidative stress, and activation of proinflammatory transcription factors, includ-
ing NF-κB [9]. At the cellular level, there is also some suggestion that aldosterone 
stimulates ROS production in humans. In human endothelial cells, spironolactone 
inhibited Nox-induced oxidative stress and increased eNOS activity [88], indicating 
a role for MR-mediated regulation of ROS in human vessels. In patients with hyper-
aldosteronism and adrenal adenomas, a number of studies have reported increased 
expression of redox-related genes and proteins including Nrf2, p22phox, HO-1, 
and proinflammatory transcription factors [89–91]. In human cardiomyocytes, 
aldosterone impairs mitochondrial function, important in redox regulation [91]. 
Despite suggestions that hyperaldosteronism promotes oxidative stress in human 
cardiovascular disease, studies using MR antagonists have not shown significant 
improvement in oxidative stress markers. Thus, Hwang and coworkers [92] demon-
strated that eplerenone-related improvement in flow-mediated dilation (a marker 
of endothelial function) was not associated with oxidative stress markers, plasma 
F2-isoprostanes, and vascular endothelial cell protein expression of nitrotyrosine 
and p47phox. In a small group of older adults with metabolic syndrome, flow-
mediated dilation, levels of oxidized low-density lipoproteins, or F2-isoprostanes 
did not improve in response to MR blockade, despite a large reduction (10 mmHg) 
in systolic blood pressure [93]. In addition, there was no effect of 1-month treat-
ment with eplerenone on oxidative stress (oxidized LDL) and arterial stiffness in 
healthy older adults [94]. However, Chen et al. [95] recently demonstrated that 
increased NADPH oxidase-dependent oxidative stress, oxidative BH4 degradation, 
eNOS uncoupling, and reduced NO generation were responsible for the impaired 
in vivo endothelial repair capacity of early endothelial progenitor cells from hyper-
tensive patients with primary hyperaldosteronism [95]. Further clinical studies are 
needed to confirm the role of ROS in aldosterone-mediated cardiovascular injury. 
Moreover, trials that assess effects of MR antagonists on ROS levels rather than 
markers of oxidative stress (oxidized LDL, F2-isoprostanes) are warranted.
6. Conclusions
Experimental evidence clearly shows that MR/aldosterone blockade decreases 
vascular oxidative stress and improves vascular function, structure, and mechani-
cal properties in different experimental models. Among the cell types involved 
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in aldosterone/MR/oxidative-associated vascular damage are endothelial cells 
and vascular smooth muscle cells. However, growing evidence suggests that these 
vascular effects can also be modulated by MR expressed in infiltrating immune cells, 
i.e., lymphocytes and macrophages, and in the surrounding perivascular adipose 
tissue that might release ROS directly impacting the endothelium and vascular 
wall. Alternatively, these cells can generate MR-dependent inflammatory cytokines 
(or adipokines) that act in a paracrine manner in the underlying vessels to induce 
oxidative stress and hence vascular damage. Thus, MR-associated oxidative stress in 
different cell types emerges as an important pathway contributing to vascular dys-
function and injury associated with conditions of high aldosterone/MR activation. 
Accordingly, it is suggested that some of the vasoprotective effects of MR antago-
nists used clinically may be mediated by inhibiting ROS-induced vascular damage.
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